-
Signature
-
/s/ Michelle Webb, Attorney-in-Fact
-
Issuer symbol
-
ACVA
-
Transactions as of
-
01 Apr 2024
-
Net transactions value
-
-$1,839,514
-
Form type
-
4
-
Filing time
-
03 Apr 2024, 17:36:27 UTC
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ACVA |
Class A Common Stock |
Tax liability |
$99,992 |
-5,470 |
-1.6% |
$18.28 |
327,857 |
01 Apr 2024 |
Direct |
F1 |
| transaction |
ACVA |
Class A Common Stock |
Tax liability |
$116,663 |
-6,382 |
-1.9% |
$18.28 |
321,475 |
01 Apr 2024 |
Direct |
F1 |
| transaction |
ACVA |
Class A Common Stock |
Conversion of derivative security |
|
+78,259 |
+24% |
|
399,734 |
02 Apr 2024 |
Direct |
F2 |
| transaction |
ACVA |
Class A Common Stock |
Sale |
$1,406,314 |
-78,259 |
-20% |
$17.97 |
321,475 |
02 Apr 2024 |
Direct |
F3, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ACVA |
Class B Common Stock |
Tax liability |
$216,545 |
-11,846 |
-2.5% |
$18.28 |
455,426 |
01 Apr 2024 |
Class A Common Stock |
11,846 |
|
Direct |
F1, F2, F5 |
| transaction |
ACVA |
Class B Common Stock |
Conversion of derivative security |
$0 |
-78,259 |
-17% |
$0.000000 |
377,167 |
02 Apr 2024 |
Class A Common Stock |
78,259 |
|
Direct |
F2, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: